How much does Lipitor (atorvastatin) lower heart disease risk?
Lipitor (atorvastatin) lowers the risk of major cardiovascular events in people with established heart disease and in people at elevated risk.
In large clinical trial data summarized by the FDA, atorvastatin reduced:
- Risk of cardiovascular death and heart attack (nonfatal MI) combined by about 36% versus placebo over about 4 years in one major study [1].
- Risk of stroke by about 27% versus placebo over about 4 years in that same study [1].
Those effects reflect reduction in “major adverse cardiovascular events” rather than a single outcome, and the size of benefit depends on baseline risk (how likely heart disease events were before treatment).
What endpoints were used to measure Lipitor’s benefit?
Trial results for Lipitor are typically reported as composite cardiovascular endpoints (a mix of events), such as cardiovascular death, nonfatal myocardial infarction (heart attack), and stroke, compared with placebo over multi-year follow-up [1]. The FDA labeling also presents separate relative risk reductions for key individual outcomes like stroke [1].
Does Lipitor lower risk in people with and without prior heart attacks?
Yes. The labeling data show reductions in major cardiovascular outcomes in both:
- People with existing cardiovascular disease (secondary prevention) [1]
- People with risk factors but without known cardiovascular disease (primary prevention) [1]
Because the absolute risk reduction depends on baseline risk, two people can have the same relative percentage reduction but different absolute benefit.
How to interpret “percent risk reduction” vs “absolute risk”
Clinical trials often report relative reductions (for example, 36% fewer cardiovascular death or nonfatal MI events) [1]. Absolute risk reduction is the real-world difference in event rates over time and depends on your starting risk level (age, diabetes, prior events, smoking, cholesterol levels, blood pressure). If you share your age and whether you’ve had a heart attack or stroke, you can estimate absolute benefit more meaningfully.
What does this mean compared with “lowering cholesterol”?
Lipitor lowers LDL cholesterol, but the main question in heart disease risk is whether fewer clinical events occur. In the FDA-labeled trials, the measured reductions in heart attack, cardiovascular death, and stroke outcomes came from statin treatment over years of follow-up [1].
Sources
- FDA. “Lipitor (atorvastatin calcium) Tablets Label” (includes trial results showing relative risk reductions for cardiovascular death/MI and stroke). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020702